NS

Neeta Singh

Active Director Director DIN 09090829
DIN 09090829 First appointment Mar 2021 Primary industry Healthcare
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Mar 2021
Shareholding value •••• Premium profile

About Neeta Singh

Data last updated:

Neeta Singh is a Director at Flange Pharmaceuticals Private Limited (since 2021). The company operates in Healthcare. Flange Pharmaceuticals Private Limited reported revenue of ₹28.4 Lakh (FY 2025).

DIN 09090829
Primary Designation Director
Industry Healthcare
First Appointment 02 Mar 2021
Oldest Company Age 10 yrs
Largest company Flange Pharmaceuticals Private Limited · ₹28.4 Lakh (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director02 Mar 20212016₹28.4 Lakh (FY 2025)Active

Board colleagues of Neeta Singh

Directorship timeline

Open interactive timeline →
Flange Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Neeta Singh

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Neeta Singh

Neeta Singh currently holds 1 directorship: Flange Pharmaceuticals Private Limited (Director, since 02 Mar 2021, revenue ₹28.4 Lakh (FY 2025)).

Neeta Singh was first appointed on 02 Mar 2021 as Director at Flange Pharmaceuticals Private Limited.

The current boards of Neeta Singh's companies include Rashmi Singh (Flange Pharmaceuticals Private Limited), Vijay Bahadur Singh (Flange Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available